Lapsed, fee not paidUS 8,569,381 B2
Biotech & Lab · US 8,569,381 B2
Lapsed, fee not paid
Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
US 8,569,446 B2 · Assignee: Nymox Corporation · Inventors: Averback; Paul et al.
Overview
Drawings on their way
This patent has 7 drawing sheets. They are being downloaded; every one is in the USPTO PDF now.
Open the USPTO PDFFull text on its way
This patent is listed from its USPTO record because it passed every check. Its abstract, claims and description are being downloaded from USPTO and will appear here within days. Until then, read it in the USPTO PDF or on Google Patents.
Why it's free to use
- The USPTO Official Gazette of December 23, 2025 lists it as expired on October 29, 2025 for an unpaid maintenance fee.
- It isn't on any reinstatement notice published since.
- Its 9 US relatives have also lapsed, expired or never issued.
- We check US rights only. Check foreign counterparts before selling abroad.
FiledOctober 11, 2012
GrantedOctober 29, 2013
Expired (fee)October 29, 2025
Application number13/649632
Classification (CPC)C07K14/4711 +7 more
Length37 pages
Drawings 7
The 7 drawing sheets are on the way. Every sheet is in the USPTO PDF.
Claims
On their way
The claims are being downloaded from USPTO and will appear here within days. Until then, read it in the USPTO PDF or on Google Patents.
Description
On its way
The description is being downloaded from USPTO and will appear here within days. Until then, read it in the USPTO PDF or on Google Patents.
Timeline & family
Timeline From USPTO dates
Maintenance fees
Fees are due 3.5, 7.5 and 11.5 years after grant. This patent expired on October 29, 2025, so the fee marked "not paid" was the one that went unpaid.
3.5-year feeDue April 29, 2017Paid
7.5-year feeDue April 29, 2021Paid
11.5-year feeDue April 29, 2025Not paid
US family 10 documents, by filing date
Published applicationUS 2003/0166569 A1
Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
Filed Nov 2002 · published Sep 2003Published application
PatentUS 7,317,077 B2
Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
Filed Nov 2002 · granted Jan 2008Patent, expired (term ended)
Published applicationUS 2005/0032704 A1
Peptides effective in the treatment of tumors and other conditions requiring the removal ordestruction of cells
Filed Oct 2004 · published Feb 2005Published application
PatentUS 7,408,021 B2
Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
Filed Oct 2004 · granted Aug 2008Patent, expired (term ended)
Published applicationUS 2009/0022743 A1
Peptides Effective in the Treatment of Tumors and Other Conditions Requiring the Removal or Destruction of Cells
Filed Jul 2008 · published Jan 2009Published application
PatentUS 8,293,703 B2
Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
Filed Jul 2008 · granted Oct 2012Patent, expired (term ended)
Published applicationUS 2009/0286742 A1
Peptides Effective in the Treatment of Tumors and Other Conditions Requiring the Removal or Destruction of Cells
Filed Jun 2009 · published Nov 2009Published application
PatentUS 7,745,572 B2
Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
Filed Jun 2009 · granted Jun 2010Patent, expired (term ended)
Published applicationUS 2013/0040900 A1
PEPTIDES EFFECTIVE IN THE TREATMENT OF TUMORS AND OTHER CONDITIONS REQUIRING THE REMOVAL OR DESTRUCTION OF CELLS
Filed Oct 2012 · published Feb 2013Published application
This documentUS 8,569,446 B2
Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
Filed Oct 2012 · granted Oct 2013Lapsed, fee not paid
Earlier publications, parents and continuations. None of them can still be enforced, or this patent would not be listed.
US patents it cites 0
No US citations on record.
Sources & verification
Verification
- The USPTO Official Gazette of December 23, 2025 lists it as expired on October 29, 2025 for an unpaid maintenance fee.
- It isn't on any reinstatement notice published since.
- Its 9 US relatives have also lapsed, expired or never issued.
- Rechecked against USPTO records every day.
- We check US rights only. Check foreign counterparts before selling abroad.
Confirm it yourself
- Open the file history on Patent Center.
- The status should read "Patent Expired Due to NonPayment of Maintenance Fees Under 37 CFR 1.362".
- Check the documents for any later petition to revive or reinstate.
Official USPTO records
USPTO Official GazetteNotice of Expiration of Patents Due to Failure to Pay Maintenance Fee, issue of December 23, 2025.Where this listing came fromMaintenance fee recordEnter the patent number to see its fee history.USPTO FeesFull published documentText and every drawing sheet as a PDF.USPTOFile historyStatus, office actions, notices, fee records and petitions.USPTO Patent CenterPatent Public Search recordSearchable full text and bibliographic data.USPTO
Everything on this page comes from the documents linked above.